<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0A7D5F0-2767-4BED-A50A-595CA7E4B688"><gtr:id>A0A7D5F0-2767-4BED-A50A-595CA7E4B688</gtr:id><gtr:name>Department of Health (DH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A"><gtr:id>87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A</gtr:id><gtr:name>University of Sao Paolo</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0CD503E6-6815-4C9E-9CA8-6EF7B94FD408"><gtr:id>0CD503E6-6815-4C9E-9CA8-6EF7B94FD408</gtr:id><gtr:name>State University of Campinas</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E004D198-2D95-4A20-BBA5-B10F5B0E1753"><gtr:id>E004D198-2D95-4A20-BBA5-B10F5B0E1753</gtr:id><gtr:name>Instituto Butantan</gtr:name><gtr:address><gtr:line1>Vital Brazil Avenue, 1500</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:department>Clinical Sciences</gtr:department><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A7D5F0-2767-4BED-A50A-595CA7E4B688"><gtr:id>A0A7D5F0-2767-4BED-A50A-595CA7E4B688</gtr:id><gtr:name>Department of Health (DH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A"><gtr:id>87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A</gtr:id><gtr:name>University of Sao Paolo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0CD503E6-6815-4C9E-9CA8-6EF7B94FD408"><gtr:id>0CD503E6-6815-4C9E-9CA8-6EF7B94FD408</gtr:id><gtr:name>State University of Campinas</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E004D198-2D95-4A20-BBA5-B10F5B0E1753"><gtr:id>E004D198-2D95-4A20-BBA5-B10F5B0E1753</gtr:id><gtr:name>Instituto Butantan</gtr:name><gtr:address><gtr:line1>Vital Brazil Avenue, 1500</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/02405512-3310-4E12-AF21-E7777A3BEA1B"><gtr:id>02405512-3310-4E12-AF21-E7777A3BEA1B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Gordon</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7A3743E3-5740-4786-9B80-60647DB9139F"><gtr:id>7A3743E3-5740-4786-9B80-60647DB9139F</gtr:id><gtr:firstName>Eliane</gtr:firstName><gtr:otherNames>Namie</gtr:otherNames><gtr:surname>Miyaji</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FC81D929-4106-404F-8E94-4B66DD7F4224"><gtr:id>FC81D929-4106-404F-8E94-4B66DD7F4224</gtr:id><gtr:firstName>Daniela</gtr:firstName><gtr:otherNames>M.</gtr:otherNames><gtr:surname>Ferreira</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK01188X%2F1"><gtr:id>74AC70A6-8FE8-4BE9-A28D-8294782FCD0D</gtr:id><gtr:title>MRC/FAPESP - bilateral agreement: Multiple-epitope vaccine to confer serotype-independent protection against pneumonia</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K01188X/1</gtr:grantReference><gtr:abstractText>Pneumococcal infections account for 11% of all deaths in children under 5 years of age and in older adults, Streptococcus pneumoniae is the leading cause of community-acquired pneumonia. Pneumococcal infections in both children and adults are potentially preventable by vaccination but current vaccines do not offer the level of protection needed. Furthermore, the use of polysaccharide conjugate vaccine is associated with disease caused by non-vaccine types, a phenomenon known as serotype replacement. The existence of &amp;gt;90 different pneumococcal types implies that serotype replacement will be a persistent problem for anti-capsular vaccines. The development of a vaccine based on pneumococcal proteins common to all strains offers the potential for serotype-independent protection and the complete eradication of carriage. 
Pneumococcal surface proteins A (PspA) and Pneumococcal surface protein C (PspC) among the most promising candidates for a protein-based vaccine. Although these proteins are variable among different clinical isolates, we have found some variants that are able to induce antibodies with broad reactivity, recognizing different PspA and PspC variants. We have also shown that fusion of PspA protein fragments is an efficient strategy to extend protection provided by a protein, but the ideal epitopes (parts of the protein) to be included in the vaccine has yet to be defined. The selection of epitopes capable of inducing antibodies with broad cross-reactivity (able to recognize all variants of PspA and PspC) is of clinical importance to the successful development of a vaccine using this approach. 
We will use peptide array techniques to describe the entire range of cross-reactive epitopes target by sera that are known to be cross-reactive (murine immunized and human sera) and determine the optimal epitopes to be included in the vaccine. The approach of using peptide arrays has been successful used to identify immunogenic epitopes of candidates for Plasmodium and Leptospira vaccine but not yet for S. pneumoniae. 
Our group at LSTM has successful established an Experimental Human Pneumococcal Carriage (EHPC) model and has established pneumonia patient cohorts. We will use a unique set of pre- and post-pneumococcal intranasal inoculation samples to dissect responses to PspA and PspC epitopes to a known carriage event. We will use samples from pneumonia patients to compare healthy and susceptible antibody function. Results obtained in a previous experimental human carriage study showed that presence of serum antibodies against PspA correlated with failure to establish carriage. We have observed increased antibody responses to PspA and PspC in serum, nasal wash and bronchoalveolar lavage following carriage. Immunoglobulin reponses to exposure, carriage and disease are different and show compartmentalization. 
There is an urgent need for a pneumonia vaccine that is effective in childhood and in old age. We propose that an optimal vaccine will protect both age groups against pneumonia caused by all serotypes of pneumococci. We will achieve this by identifying epitopes of PspA and PspC to produce a multiple-epitope vaccine, test this vaccine in murine models of invasive disease and confirm cross-reactivity of antibodies using a wide panel of pneumococcal clinical isolates. Further we will use the effective acquired immunity that protects healthy adults against carriage and the deficient response of pneumonia patients to determine the effective levels and function of antibodies to this vaccine candidate. Finally, we will confirm induction of cellular responses elicited by immunisation in mice and the presence of multiple-epitope antigen specific CD4 T cells in healthy adults and pneumonia patients.</gtr:abstractText><gtr:technicalSummary>Invasive pneumococcal disease is a leading cause of morbidity and premature mortality around the world. Although current vaccination strategies are effective, they have major limitations such as low levels of protection against pneumonia and serotype replacement. 
We have conducted extensive basic laboratory and clinical translational research that has substantially improved our understanding of the limitations of current vaccines and provided insights into new approaches for vaccine development. 
We now propose a collaborative project between BI and LSTM that draws on previous successful projects to identify targets for a completely new type of pneumonia vaccine that will confer serotype-independent protection against pneumonia. 
Pneumococcal surface protein A (PspA) and Pneumococcal surface protein C (PspC) are among the most promising vaccine candidates but they exhibit antigen variability. We will describe the entire range of PspA and PspC peptides in peptide arrays that will be probed with serum from immunized mice and adults exposed to pneumococci during experimental carriage to identify optimal cross-reacting epitopes to be included in a multiple-epitope vaccine.
We will test the protective potential of this vaccine in murine models and serum cross-reactivity in in vitro assays. We will confirm induction of cellular responses in immunized mice and the presence of multiple-epitope antigen specific CD4 T cells in healthy adults and pneumonia patients after ex-vivo stimulation. We will determine responses to vaccine associated with protection from experimental human pneumococcal carriage and with susceptibility to pneumonia disease. 
These experiments will add a novel approach to protein vaccine discovery and knowledge regarding optimal vaccination strategy for mucosal protection.</gtr:technicalSummary><gtr:potentialImpactText>The impact of this grant will be mainly on the partner Institutions and the development of a novel collaboration. Our Institutions are of similar age and have committed to serve least served populations. The Butantan Institute (BI) has a long standing expertise in vaccine technology that is novel to Liverpool School of Tropical Medicine (LSTM). LSTM has wide international links and an experimental/ medicine platform that is novel to BI.
1. Impact of the collaboration on partner Institutions 
I. Change in the culture of organizations (LSTM and BI). We intend to add vaccine research to LSTM portfolio and improve BI international collaboration and international exposure. Vaccine research has long been the focus of BI effort but is new to the LSTM portfolio. 
II. Attract R&amp;amp;D investment: LSTM will help BI to partner with a UK vaccine production company.
BI has expertise in technology transfer for vaccine production. BI will gain from partnership with a UK based vaccine company to transfer technology for production of other vaccines important to Brazil and other least economically developed countries (LEDC).
2. Impact on project staff and students
I. International exposure: BI researchers will gain from enhanced impact publications, international collaborators and conferences. International exposure will bring more international collaborators and joined grant applications. 
II. Collaborative training: C Vadesilho (MSc student) and the PhD student that will continue the Multiple-epitope project at BI will have the opportunity of internships in the LSTM laboratory. BI students will gain from opportunity of visiting and work in an international laboratory environment. All LSTM staff will gain from the exchange of knowledge and experience during visit of international students and researchers. Staff will also benefit from future grant applications.
3. Impact on general public
I. Public involvement: General public will gain knowledge that will be disseminated during &amp;quot;Meet the public days&amp;quot; and school visits, which are regular events on both institutions. BI and LSTM have a strong past record of successful public engagement and are committed to improving the public understanding of science.
4. Impact on vulnerable populations
I. LSTM and BI have close collaboration with least economically developed countries (LEDC). The global burden of pneumococcal disease is highest in vulnerable LEDC and a successful vaccine will be targeting particularly those LEDC that do not have a pneumococcal vaccine in their national immunization program. Vulnerable population living in these countries such as woman, children and HIV population will benefit from a new vaccine. 
5. Vaccination Policy
I. Vaccine success will impact in change of vaccination policy. BI is affiliated with Ministry of Health in Brazil and both produces vaccines used in the Brazilian vaccine programme and advices in vaccination policy. Our results will directly feed into a body of work that is used to inform government on vaccination strategy.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-02-29</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>233108</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Health (DH)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Human Tissue Authority (HTA)</gtr:department><gtr:description>UK influenza research networks</gtr:description><gtr:id>264D8EAA-2D12-46B1-B841-0AD3D03AC7C5</gtr:id><gtr:impact>Publications, planned new studies.</gtr:impact><gtr:partnerContribution>Major recruiting site for MOSAIC study (WT/MRC) and planned key site for ASAP study (NIHR HTA).</gtr:partnerContribution><gtr:piContribution>During the H1N1 pandemic, Liverpool recruited as two of four sites for the MOSAIC consortium. Subsequently, we are poised as partners in the HTA funded ASAP study to study the effect of steroids should pandemic influenza recur. Partnerships led by Prof P Openshaw and Dr WS Lim.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Instituto Butantan</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:department>Biotechnology Centre</gtr:department><gtr:description>Bilateral Partnership LSTM/BI</gtr:description><gtr:id>EFC50DCE-7463-43E8-8DE5-91FEAA746909</gtr:id><gtr:impact>Internship of Cintia Vadesilho
LSTM PhD award to Jessica Owugha
Eliane Miyaji's visit at LSTM
Daniela Ferreira's visit at BI</gtr:impact><gtr:partnerContribution>Butantan Institute has provided important advice on pneumococcal protein discovery as well as supplied LSTM lab with several recombinant proteins and DNA plasmids for protein expression.</gtr:partnerContribution><gtr:piContribution>We have received visiting students from Butantan Institute. Two students (Adriana Moreno and Cintia Vadesilho) have visited our laboratory at LSTM for 3 months each. They gained from the experience of being part of a research laboratory team during their PhD and MSc studies.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>State University of Campinas</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Science without Borders</gtr:description><gtr:id>E866612F-7768-4309-8074-04DB9DDF5FFB</gtr:id><gtr:impact>tbc</gtr:impact><gtr:partnerContribution>TBC</gtr:partnerContribution><gtr:piContribution>Launched LSTM PhD SwB Programme and went to Brazil on a tour of Universities to attract bright PhD students to LSTM. 3 Brazilian students have applied to the programme this year.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sao Paulo</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Science without Borders</gtr:description><gtr:id>2E5E991B-4DA9-457B-878D-5A898AADF3EB</gtr:id><gtr:impact>tbc</gtr:impact><gtr:partnerContribution>TBC</gtr:partnerContribution><gtr:piContribution>Launched LSTM PhD SwB Programme and went to Brazil on a tour of Universities to attract bright PhD students to LSTM. 3 Brazilian students have applied to the programme this year.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Jenner Institute</gtr:department><gtr:description>Computational approaches to common conserved epitope to 30 antigens</gtr:description><gtr:id>3B3192E5-64B6-4C71-B000-6D9529F140DB</gtr:id><gtr:impact>TBC</gtr:impact><gtr:partnerContribution>TBC</gtr:partnerContribution><gtr:piContribution>Ongoing collaboration with Dr Arturo Reyes-Sandoval</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Liverpool School of Tropical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Science without Borders</gtr:description><gtr:id>394CCE7D-042E-4E03-9DC9-164A2AB45DC1</gtr:id><gtr:impact>tbc</gtr:impact><gtr:partnerContribution>TBC</gtr:partnerContribution><gtr:piContribution>Launched LSTM PhD SwB Programme and went to Brazil on a tour of Universities to attract bright PhD students to LSTM. 3 Brazilian students have applied to the programme this year.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BREATHE theme leaders visit Malawi CAPS sites</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D6DB2812-9366-4FBA-AD87-D69E2F9BE376</gtr:id><gtr:impact>We planned exposure monitoring for 10000 children, and wrote 2 new grants.

New grants including MRC NIRG and NIH RO1</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.capstudy.org/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dr Eliane Miyaji (Butantan Institute) Visit to LSTM</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E1A33102-DEFE-4EDB-B54E-68B4796B4A46</gtr:id><gtr:impact>As part of the LSTM and Butantan Institute collaboration underpinned by the MRC/FAPESP and MRC Programme grant awards Dr Miyaji visits LSTM annually to disseminate results findings and discuss next steps of this collaboration.

TBC</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Facebook page</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>90EA5B1C-F695-444E-8526-A7A548B34F6D</gtr:id><gtr:impact>Facebook page advertises studies and informs on latest study developments, currently over 60 members and a footprint of over 1000 people</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/LivRRC/?ref=aymt_homepage_panel</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biological Challenges of effective vaccines - Royal Society, London</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1F9B1922-99B9-4F95-AD50-335B2FE8771A</gtr:id><gtr:impact>This satellite meeting discussed recent findings and challenge participants to identify key research questions that will yield more effective vaccines in low-income countries.

My talk was discussed on twitter by Pathogens</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>keynote/invited speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Tokyo - EHPC collaboration meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07FF2FA0-C613-4986-AA6D-48A7E7ED8C50</gtr:id><gtr:impact>A meeting between LSTM and Tokyo university to discuss the a joint grant application to the MRC DPFS as part of a new collaboration to develop mucosal vaccines based on PspA antigen. This collaboration resulted from the visit of Dr Ferreira to Butantan Institute (Sao Paulo) as part of the MRC/FAPESP award.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annually Invited Lecture at Butantan Institute, Sao Paulo, Brazil</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2102A372-CD42-442C-8092-964BB37D0F98</gtr:id><gtr:impact>As part of the collaboration between LSTM and Butantan Institute underpinned by the MRC/FAPESP and MRC Programme grant awards DF visits Butantan annually and give a talk about project results aimed at all researchers and students at the Institute

tbc</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Research Council - UK-Brazilian Infectious Disease workshop</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>47509AAA-DC46-4061-9280-3FEC09AD3E51</gtr:id><gtr:impact>The objective of the workshop will be 2 fold, not only to identify specific individual collaborations but also to scope out and inform the joint UK-Brazilian call in the area of infectious disease, which will be launched under the Newton Fund next year.

scope out and inform the joint UK-Brazilian call in the area of infectious disease, which will be launched under the Newton Fund next year.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Daniela Ferreira - visit and talk at BI</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8779E774-61D4-4DC5-8EA8-D22FFB0691AD</gtr:id><gtr:impact>Daniela Ferreira visited Butantan Institute (BI- (Sao Paulo, Brazil) on the 17th and 18th of October 2013. Daniela met with collaborators Paulo Lee Ho, Maria Leonor Oliveira and Eliane Miyaji and gave a talk on &amp;quot;Experimental Human Pneumococcal Carriage for vaccine research&amp;quot; that was attended by 30 researchers and students.

During this visit it was discussed a possible laboratory internship of Jessica Owugha (PhD LSTM) to Butantan Institute and further grant applications relating to the Me vaccine project (MR/K01188X/1).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XII European Meeting on the Molecular Biology of the Pneumococcus, Europneumo, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>165FB15A-B4A9-4B5D-A5A3-DC5243F9F154</gtr:id><gtr:impact>Talk to disseminate research findings during this conference. Breakfast meeting with approximately 20 EHPC collaborators to discuss the EHPC Programme planned activities.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>9th International Symposium on Pneumococci and Pneumococcal Diseases, ISPPD-9, India</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>76912ED3-24D2-4471-8BA2-D07D10EFCE6B</gtr:id><gtr:impact>Talk to disseminate research findings and discussion of future collaborative activities

tbc</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Human Challenge Models workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8568CCFF-C921-4F9C-B089-D0AD629DC939</gtr:id><gtr:impact>Lancet Infectious Diseases report as per papers

MRC Programme grant Expt Human Pneumococcal Carriage funded Nov 2014</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Twitter Feed (@Liv_RRN)</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>864F9A68-0568-4FD2-86A9-AF097F655BDE</gtr:id><gtr:impact>Twitter feed used to encourage study participation and inform donors and collaborators of current policy</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Academic visit and Talk at Butantan Institute and University of Sao Paulo.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3040A9B3-B6D9-4C46-AD60-449C18771774</gtr:id><gtr:impact>Postgraduate, undergraduate students and principal investigators attended these two seminars which sparked questions and discussion afterwards. This visit initiated the visit of two academics from Brazil to the LSTM in 2017 (Helder Nakaya and Alessandra Schanoski).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Eliane Miyaji - visit and talk at LSTM</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>3EB415A3-7B32-41CA-8BCB-DDA929C8E009</gtr:id><gtr:impact>Eliane Miyaji (Butantan Institute) visited the Liverpool School of Tropical Medicine (LSTM) on the 4rd and 5th of June of 2013 to meet Stephen Gordon and Daniela Ferreira and to discuss results related to the Me vaccine project (MR/K01188X/1). During this visit she has presented a talk on &amp;quot;Pneumococcal vaccines based on PspA and other choline-binding proteins&amp;quot; that was attended by 20 researchers from LSTM, University of Liverpool and John Moores University.

This visit has raised the profile of Butantan Institute and Eliane has had the opportunity to discuss further collaborations. As a result Imran Saleem (John Moores University) is preparing a grant proposal in collaboration with Eliane Miyaji and Viviane Goncalves (Butantan Institute) under the BBSRC/FAPESP bilateral agreement</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.lstmliverpool.ac.uk/events/june-2013/4-june-eliane-miyaji/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>41178</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LSTM PhD award of Jessica Owugha</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Liverpool School of Tropical Medicine</gtr:fundingOrg><gtr:fundingRef>LSTM 200499290</gtr:fundingRef><gtr:id>C917DCB9-C346-448C-BB04-E752552B6652</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2282780</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Experimental Human Pneumococcal Carriage to determine optimal protection from carriage and mechanisms of mucosal immunisation against disease</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>N/A</gtr:fundingRef><gtr:id>FBA70D07-59A5-4DF3-8DB7-371C3C04640F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1180000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A phase 2, randomized double-blind placebo-controlled study to evaluate the safety, tolerability and efficiacy of GEN-004</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Genocea Biosciences</gtr:fundingOrg><gtr:fundingRef>50190</gtr:fundingRef><gtr:id>8FDFDC79-DC7D-4E7F-AB29-6CDD27F02AFD</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>523377</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Enhancing mucosal immunity to Streptococcus pneumoniae by nasal administration of live strains attenuated in virulence</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/N02687X/1</gtr:fundingRef><gtr:id>6396348D-AC77-4C60-8987-DEF62F5EADE3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>456762</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Vaccine Fapesp MICA : Pulmonary Delivery of a Targeted Mucosal Nanocarrier Vaccine for Pneumonia</gtr:description><gtr:end>2020-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>420EBF40-0232-4F68-A8D9-B5EBF9B39523</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2470</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Jean Clayton Travel Award - Jessica Owugha</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Liverpool School of Tropical Medicine</gtr:fundingOrg><gtr:id>398ADB97-452B-4E95-B6FA-77619DADB072</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4460</gtr:amountPounds><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Studentship Cintia Vadesilho for peptide array discovery at LSTM</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>FAPESP</gtr:fundingOrg><gtr:id>B85C4DDA-8A4C-4DC4-8DA0-46186C09274D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2518294</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Effect of Live Attenuated and Inactivated Influenza vaccines on Experimental Human Pneumococcal Carriage</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1117728</gtr:fundingRef><gtr:id>19FB0E32-2680-495B-A28E-10BF74E8B4E2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>GEN-004 is a recombinant Streptococcus pneumoniae protein subunit vaccine consisting of 3 recombinant antigens. Aluminium hydroxide is used as an adjuvant. In a Phase 1 study, GEN-004 met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of TH17 cells. The randomized, double-blind, dose-escalation, placebo-controlled clinical trial included approximately 90 healthy adult volunteers.</gtr:description><gtr:id>8B81B814-DA7F-4AEC-8D48-30A3C5F78408</gtr:id><gtr:impact>tbc</gtr:impact><gtr:status>Under active development/distribution</gtr:status><gtr:title>GEN-004 is a recombinant Streptococcus pneumoniae protein subunit vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>17331</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B54A225B-5E40-4049-8C7B-FC1D2EE34ECF"><gtr:id>B54A225B-5E40-4049-8C7B-FC1D2EE34ECF</gtr:id><gtr:title>Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/781ae3f1038e660ba69f20caf2de236e"><gtr:id>781ae3f1038e660ba69f20caf2de236e</gtr:id><gtr:otherNames>Collins AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EE5C329-B02F-46E8-9BE9-0D1164759A31"><gtr:id>3EE5C329-B02F-46E8-9BE9-0D1164759A31</gtr:id><gtr:title>Experimental human pneumococcal carriage augments IL-17A-dependent T-cell defence of the lung.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/96af351589f87a92b5f680c20d236494"><gtr:id>96af351589f87a92b5f680c20d236494</gtr:id><gtr:otherNames>Wright AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11AE05A6-A4F7-4E9A-9275-FAF7AC64ECEF"><gtr:id>11AE05A6-A4F7-4E9A-9275-FAF7AC64ECEF</gtr:id><gtr:title>Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.</gtr:title><gtr:parentPublicationTitle>Clinical and vaccine immunology : CVI</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23ee85a13e3443550153259ac149b546"><gtr:id>23ee85a13e3443550153259ac149b546</gtr:id><gtr:otherNames>Vadesilho CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1556-679X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E94CD53-D471-43A3-B059-9447963BEEAA"><gtr:id>3E94CD53-D471-43A3-B059-9447963BEEAA</gtr:id><gtr:title>Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/acfb1674ee4f50814fc8a7e1a1e67b6f"><gtr:id>acfb1674ee4f50814fc8a7e1a1e67b6f</gtr:id><gtr:otherNames>Pennington SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F4E148E-AE18-4B1D-844E-F4A2E33544BE"><gtr:id>8F4E148E-AE18-4B1D-844E-F4A2E33544BE</gtr:id><gtr:title>Modulation of nasopharyngeal innate defenses by viral coinfection predisposes individuals to experimental pneumococcal carriage.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/51a033d0f811e26555cef3a06f25b55a"><gtr:id>51a033d0f811e26555cef3a06f25b55a</gtr:id><gtr:otherNames>Glennie S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27D54ACD-278F-4A8D-A7AB-156F70888F08"><gtr:id>27D54ACD-278F-4A8D-A7AB-156F70888F08</gtr:id><gtr:title>Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8821414bf5a4872f0a5d9944b6b932e9"><gtr:id>8821414bf5a4872f0a5d9944b6b932e9</gtr:id><gtr:otherNames>Kunda NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0B9788AB-FB8A-467F-A237-6A5FAAE140DF"><gtr:id>0B9788AB-FB8A-467F-A237-6A5FAAE140DF</gtr:id><gtr:title>Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50a4a8c256eeaf303234868884de9b46"><gtr:id>50a4a8c256eeaf303234868884de9b46</gtr:id><gtr:otherNames>Ferreira DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K01188X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>